Depression trials recruiting in Ohio

All Depression trials nationally

Cities in Ohio

Recruiting trials in Ohio

• A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety
  NCT06820723 · Phase: Phase 2 · Ages: 21 Years to 65 Years · Sex: All (male and female) · Ohio: Columbus
• A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
  NCT07115329 · Phase: Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female) · Ohio: Independence
• A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
  NCT07592689 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Ohio: Cleveland
• A Precision Medicine Approach to Target Engagement for Emotion Regulation
  NCT05651295 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Columbus
• A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
  NCT03887715 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland, Columbus, Fairlawn, Garfield Heights
• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
  NCT06775379 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Ohio: North Canton
• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
  NCT07076407 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Ohio: Independence
• A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
  NCT07573176 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Ohio: Cincinnati
• A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
  NCT06696755 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Ohio: Cincinnati, Columbus
• A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
  NCT04777357 · Phase: Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female) · Ohio: Avon Lake, Cincinnati, Cleveland, West Chester
• A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
  NCT07276997 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Ohio: Avon Lake, Columbus
• A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
  NCT06524830 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Ohio: Columbus, North Canton
• A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
  NCT07610473 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Ohio: Columbus
• A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
  NCT07105111 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Independence
• A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
  NCT07227454 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · Ohio: Cincinnati
• A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
  NCT07065240 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Ohio: Independence, North Canton
• A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
  NCT06223880 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Ohio: Cincinnati
• ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
  NCT07284667 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Ohio: North Canton
• ALTO-100 in Bipolar Disorder With Depression (BD-D)
  NCT06656416 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Ohio: North Canton, Westlake
• ALTO-207 in Adults With Treatment-resistant Depression (TRD)
  NCT07553637 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Ohio: Cincinnati, Garfield Heights
• Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)
  NCT04245436 · Phase: Phase 4 · Ages: 12 Years to 17 Years · Sex: All (male and female) · Ohio: Cincinnati
• BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and Early Post-Childbirth Women
  NCT07413692 · Phase: Not applicable (e.g. observational or device study) · Ages: 22 Years to 60 Years · Sex: Female · Ohio: Garfield Heights
• Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
  NCT07484217 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Ohio: Cincinnati
• Developing Resilience and Anxiety Management Through the Arts
  NCT07033052 · Phase: Not applicable (e.g. observational or device study) · Ages: 8 Years to 17 Years · Sex: All (male and female) · Ohio: Cleveland
• E-Mindfulness Approaches for Living After Breast Cancer
  NCT06748222 · Phase: Phase 3 · Ages: 18 Years to 50 Years · Sex: All (male and female) · Ohio: Beavercreek, Cincinnati, Columbus, Findlay
• HeartGPS: A Study Exploring the Effects of a Psychological Intervention for Parents and Their Babies After Prenatal Cardiac Diagnosis
  NCT06175104 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cincinnati
• Improving Outcomes in Adolescent Inpatient Depression With Deep Transcranial Magnetic Stimulation
  NCT07217444 · Phase: Not applicable (e.g. observational or device study) · Ages: 14 Years to 18 Years · Sex: All (male and female) · Ohio: Cincinnati
• Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06966401 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Avon Lake
• Mechanisms of Rumination Change in Adolescent Depression
  NCT03859297 · Phase: Not applicable (e.g. observational or device study) · Ages: 14 Years to 17 Years · Sex: All (male and female) · Ohio: Columbus
• Mindfulness-based Psilocybin Therapy for PTSD
  NCT07104916 · Phase: Phase 2 · Ages: 21 Years to 65 Years · Sex: All (male and female) · Ohio: Columbus
• Modulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains
  NCT06795451 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · Ohio: Mason
• Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
  NCT06372964 · Phase: Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female) · Ohio: Avon Lake, Cincinnati, Garfield Heights, Westlake
• Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
  NCT07494305 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Ohio: Canton
• NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06911112 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Mason
• Observational Study of THC Concentrations in Acute Cannabis-induced CNS Depression
  NCT06017622 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Ohio: Cincinnati
• Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
  NCT06559306 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Ohio: Avon Lake, Cincinnati, Columbus, Middleburg Heights
• Positive Processes and Transition to Health (PATH)
  NCT06093906 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female) · Ohio: Cleveland
• Positive Processes and Transition to Health - Single-Session (PATH-SS)
  NCT06900712 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female) · Ohio: Cleveland
• Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth
  NCT07464886 · Phase: Phase 3 · Ages: 15 Years to 24 Years · Sex: All (male and female) · Ohio: Cincinnati
• Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer
  NCT07216404 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Columbus
• RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
  NCT07002034 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Ohio: Cleveland, Columbus
• Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
  NCT06633016 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Ohio: Beachwood
• Study of ALTO-300 in MDD
  NCT05922878 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Ohio: Cincinnati
• Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
  NCT05850689 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Ohio: Avon Lake, Cincinnati, Columbus
• Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06786624 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Avon Lake, Westlake
• TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age
  NCT07048574 · Phase: Not specified · Ages: 18 Months to 11 Years · Sex: All (male and female) · Ohio: Cincinnati
• Teenthrive 2: Treatments for Improving Mood in Teens
  NCT07475845 · Phase: Not applicable (e.g. observational or device study) · Ages: 12 Years to 18 Years · Sex: All (male and female) · Ohio: Columbus
• The Mom and Infant Outcomes (MOMI) Study
  NCT06277661 · Phase: Not applicable (e.g. observational or device study) · Ages: No age limits stated · Sex: Female · Ohio: Columbus
• Transforming Care for Individuals With Childhood-onset Systemic Lupus Erythematosus
  NCT06232304 · Phase: Not applicable (e.g. observational or device study) · Ages: 12 Years to 22 Years · Sex: All (male and female) · Ohio: Cincinnati
• Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
  NCT06423430 · Phase: Not applicable (e.g. observational or device study) · Ages: 22 Years to 70 Years · Sex: All (male and female) · Ohio: Cleveland, Columbus
• Virtual Patient Groups for Sarcoidosis Associated Fatigue
  NCT07073963 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland
• Virtual Poetry Workshops to Enhance Patient Well Being and Reduce Anxiety
  NCT07717541 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Columbus
• Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
  NCT06547489 · Phase: Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female) · Ohio: Independence